1610833-03-8
1610833-03-8
Chemical Structure
Burosumab
Synonym(s): KRN23; N5KG1_C10_LH; UX-023
- CAS No.: 1610833-03-8
- Formula:N/A
- Molecular Weight:(144.08 kDa)
SMILES: [Burosumab]
Biological Activity: Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Burosumab | 99.20% | Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne). 2020 May 28;11:338. [Content Brief]
- [2]. Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int. 2022 Dec 1. [Content Brief]
- [3]. Lira Dos Santos EJ, et al. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia. Int J Oral Sci. 2023 Dec 6;15(1):53. [Content Brief]
Keywords
